Intas Pharmaceuticals has entered into an exclusive partnership with IntegriMedical to bring India’s first Needle-Free Injection System (N-FIS) to IVF and gynecology care. The collaboration positions Intas as the only company in the country to offer IVF and gynecology therapies using needle-free drug delivery, marking a major advancement in patient-centric treatment.
The agreement represents a significant step forward in women’s health, as it redefines how injectable therapies are administered during IVF and gynecological treatments. By eliminating conventional needles, the new system is designed to enhance patient comfort, reduce anxiety associated with repeated injections, and improve overall treatment adherence.
Through the partnership, Intas will deploy IntegriMedical’s proprietary needle-free technology across IVF clinics and gynecology centers nationwide. The initiative aims to streamline access to the innovation while setting a new benchmark for comfort-focused, innovative drug delivery in reproductive healthcare.
India is among the fastest-growing IVF markets globally, with an estimated 300,000–350,000 IVF cycles conducted annually a figure projected to rise to 500,000–600,000 cycles by 2027. This growth translates into millions of injections administered each year. The introduction of needle-free injections is expected to significantly improve the treatment experience for hundreds of thousands of women by easing pain, lowering anxiety, and reducing treatment fatigue.
Sarvesh Mutha, Managing Director of IntegriMedical, said the collaboration reflects a shared commitment to making medical treatments more humane and less intimidating. He noted that seeing the technology adopted at scale through Intas is a major milestone for patient-focused innovation in IVF and gynecology.
Durga P Satapathy, Executive Vice President at Intas, said the initiative goes beyond technology adoption and focuses on transforming the patient experience. He added that IVF and gynecology treatments can be physically and emotionally demanding, and innovations like N-FIS can make care more reassuring and dignified.
The Needle-Free Injection System works by delivering medication through a high-pressure jet stream that passes through a fine micro-orifice in the skin. This spray-like delivery allows effective drug administration without needles, minimizing tissue damage, preventing drug pooling, and lowering the risk of cross-contamination.
Overall, the agreement brings together Intas Pharmaceuticals’ market leadership and IntegriMedical’s technological innovation to reshape IVF and gynecology care in India, placing patient comfort and experience at the center of treatment.
